Janus Henderson Group PLC Takes $343,000 Position in Urogen Pharma $URGN

Janus Henderson Group PLC purchased a new position in Urogen Pharma (NASDAQ:URGN) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 19,100 shares of the company’s stock, valued at approximately $343,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. increased its position in Urogen Pharma by 27.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after acquiring an additional 486 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Urogen Pharma by 7.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after acquiring an additional 1,653 shares during the last quarter. Main Street Financial Solutions LLC boosted its stake in shares of Urogen Pharma by 8.2% during the 2nd quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company’s stock worth $356,000 after purchasing an additional 1,968 shares during the period. Barclays PLC boosted its stake in shares of Urogen Pharma by 3.8% during the 4th quarter. Barclays PLC now owns 57,744 shares of the company’s stock worth $1,352,000 after purchasing an additional 2,125 shares during the period. Finally, Osaic Holdings Inc. grew its holdings in Urogen Pharma by 491.2% during the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after purchasing an additional 3,070 shares during the last quarter. 91.29% of the stock is owned by hedge funds and other institutional investors.

Urogen Pharma Stock Performance

Urogen Pharma stock opened at $46.31 on Tuesday. The company has a 50 day moving average price of $36.83 and a 200-day moving average price of $27.37. Urogen Pharma has a fifty-two week low of $15.86 and a fifty-two week high of $48.19. The company has a market capitalization of $2.26 billion, a PE ratio of -23.39 and a beta of 1.57.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The company had revenue of $72.46 million during the quarter, compared to analysts’ expectations of $63.55 million. On average, analysts forecast that Urogen Pharma will post -0.2 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. HC Wainwright increased their price objective on shares of Urogen Pharma from $45.00 to $75.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $44.00 target price on shares of Urogen Pharma in a research note on Wednesday, July 15th. Guggenheim increased their price target on Urogen Pharma from $42.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday. LADENBURG THALM/SH SH began coverage on Urogen Pharma in a research note on Monday, May 11th. They set a “buy” rating and a $43.00 price target for the company. Finally, Jefferies Financial Group upgraded Urogen Pharma to a “strong-buy” rating in a report on Friday, April 24th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $48.78.

Insiders Place Their Bets

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the company’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $40.00, for a total value of $400,000.00. Following the completion of the sale, the insider directly owned 119,763 shares in the company, valued at approximately $4,790,520. This represents a 7.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 25,222 shares of company stock worth $892,661. Insiders own 4.80% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.